New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents

Nuclear Medicine and Biology

Volumn 31, Issue 4, 2004, Pages 459-468

  Oltenfreiter, Ruth ^a   Staelens, Ludovicus ^a   Lejeune, Annabelle ^b   Dumont, Filip ^a   Frankenne, Francis ^b   Foidart, Jean Michel ^b   Slegers, Guido ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

In vitro assay; In vivo biodistribution; Iodine 123; Radiolabelled MMP inhibitors; SPECT; Tumor imaging

Indexed keywords

2 (4' IODOBIPHENYL 4 SULFONYLAMINO) 3 (1H INDOL 3 YL)PROPIONAMIDE I 123; 2 (4' IODOBIPHENYL 4 SULFONYLAMINO) 3 (1H INDOL 3 YL)PROPRIONIC ACID I 123; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; TIN DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER RESEARCH; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NONHUMAN; RADIOIODINATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTITUTION REACTION; TUMOR GROWTH; ZYMOGRAPHY;

AMIDES; ANIMALS; FEASIBILITY STUDIES; IODINE RADIOISOTOPES; ISOTOPE LABELING; MATRIX METALLOPROTEINASES; METABOLIC CLEARANCE RATE; MICE; NEOPLASMS; ORGAN SPECIFICITY; PROPIONIC ACIDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 1842828874     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.10.013     Document Type: Article

References (36)

1. Zucker S., Cao J. Imaging metalloproteinase activity in vivo. Nat Med. 7:2001;655-656.
2. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1997;1260-1270.
3. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem. 274:1999;21491-21494.
4. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases biologic activity and clinical implications. J Clin Oncol. 18:2000;1135-1149.
5. Noël A., Albert V., Bajou K., Bisson C., Devy L., Frankenne F., Maquoi E., Masson V., Sounni N.E., Foidart J.M. New functions of stromal proteases and their inhibitors in tumor progression. Surg Oncol Clin North Am. 10:2001;417-432.
6. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev. 2:2002;161-174.
7. Coussens L.M., Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 3:1996;895-904.
8. Fei X., Zheng Q.H., Liu X., Wang J.Q., Sun H.B., Mock B.H., Stone K.L., Miller K.D., Sledge G.W., Hutchins G.D. Synthesis of radiolabelled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorg Med Chem Lett. 13:2003;2217-2222.
9. Vihinen P., Kähäri V.M. Matrix metalloproteinases in cancer prognostic markers and therapeutic targets. Int J Cancer. 99:2002;157-166.
10. O'Brien P.M., Ortwine D.F., Pavlovsky A.G., Picard J.A., Sliskovic D.R., Roth B.D., Dyer L.L., Johnson R.D., Man C.F., Hallak H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 43:2000;156-166.
11. Bremer C., Bredow S., Mahmood U., Weissleder R., Tung C.H. Optical imaging of matrix metalloproteinase-2 activity in tumors feasibility study in a mouse model. Radiology. 221:2001;523-529.
12. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 189:1999;300-308.
13. Fang J, Shing, Wiederschain D. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 2000;97:3884-9.
14. Furumoto S., Iwata R., Ido T. Design and synthesis of fluorine-18 labelled matrix metalloproteinase inhibitors for cancer imaging. J Label Comp Radiopharmacol. 45:2002;975-986.
15. Brown P.D., Bloxidge R.E., Anderson E., Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metast. 11:1993;183-190.
16. Cai M., Onoda K., Takao M., Kyoko I.Y., Shimpo H., Yoshida T., Yada I. Degradation of Tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrece in early stage non-small cell lung cancer. Clin Cancer Res. 8:2002;1152-1156.
17. Davies B., Miles D.W., Happerfield L.C., Naylor M.S., Bobrow L.G., Rubens R.D., Balkwill F.R. Activity of type IV collagenases in benign and malignant breast desease. Br J Cancer. 67:1993;1126-1131.
18. Furumoto S., Takashima K., Kubota K., Ido T., Iwata R., Fukuda H. Tumor detection using F-18-labelled matrix metalloproteinase-2 inhibitor. Nucl Med Biol. 30:2003;119-125.
19. Kossakowska A.E., Huchcroft S.A., Urbanski S.J. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant, non-Hodgkin's lymphomas in humans. Br J Cancer. 73:1996;1401-1408.
20. Lee K.S., Rha S.Y., Kim S.J. Seuential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis. 14:1996;512-519.
21. Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., Balkwill K. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenaes in colorectal cancer. Cancer Res. 56:1996;190-196.
22. Passlick B., Sienel W., Seen-Hibler R., Wöckel W., Thetter O., Mutschler W., Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 6:2000;3944-3948.
23. Ylisirniö S., Höyhtyä M., Turpeeniemi-Hujanen T. Serum metalloproteinasese -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res. 20:2000;1311-1316.
24. Kuhnast B., Bodenstein C., Wester H.E., Weber W. Carbon-11-labelling of an N-Sulfanylamino acid derivative a potential tracer for MMP-2 and MMP-9 imaging. J Label Compd Radiopharm. 46:2003;539-553.
25. 11C]methyl- halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol. 29:2002;761-770.
26. Hagmann W.K., Lark M.W., Becker J.W. Inhibition of matrix metalloproteinases. Bristol J.A. Annual reports in medical chemistry. 1996;231-240 Academic Press, New York.
27. Summers J.B., Davidsen S.K. Matrix metalloproteinase inhibitors and cancer. Bristol J.A. Annual reports in medical chemistry. 1998;131-140 Academic Press, New York.
28. Kiyama R., Tamura Y., Watanabe F., Tsuzuki H., Ohtani M., Yodo M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J Med Chem. 42:1999;1723-1738.
29. Tamura Y., Watanabe F., Nakatani T., Yasui K., Fuji M., Komurasaki T., Tsuzuki H., Maekawa R., Yoshioka T., Kawada K., Sugita K., Ohtani M. Higly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2) N-sulfonylamino acid derivatives. J Med Chem. 41:1998;640-649.
30. ′ pockets. J Med Chem. 44:2001;3066-3073.
31. Maquoi E., Frankenne F., Baramova E., Munaut C., Sounni N.E., Remacle A., Noël A., Murphy G., Foidart J.M. Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem. 275:2000;11368- 11378.
32. Hawkes S.P., Li H., Taniguchi G.T. Zymography and reverse zymography for detecting MMPs and TIMPs. Clark I. Methods in Molecular Biology. 2001;399-410 Humana Press, Totowa, NJ.
33. Whittaker M., Flooyd C.D., Brown P., Gearing A.J.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 99:1999;2735-2776.
34. Massa S., Artico M., Corelli F., Mai A., Di Santo R., Cortes S., Marongiu M.E., Pani A., La Colla P. Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. J Med Chem. 33:1990;2845-2849.
35. Natchus M.G., Bookland R.G., De B., Almstead N.G., Pikul S., Janusz M.J., Heitmeyer S.A., Hookfin E.B., Hsieh L.C., Dowty M.E., Dietsch C.R., Patel V.S., Garver S.M., Gu F., Pokross M.E., Mieling G.E., Baker T.R., Foltz D.J., Peng S.X., Bornes D.M., Strojnowski M.J., Taiwo Y.O. Development of new hydroxamic matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J Med Chem. 43:2000;4948-4963.
36. Scozzafava A., Supuran C.T. Protease inhibitors Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. J Med Chem. 43:2000;1858-1865.